[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CSPC Ouyi Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":193},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,62,87,108,130,151,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100637657","phase-3-a-clinical-study-to-evaluate-the-efficacy-and-safety-of-bempedoic-acid-100637657",false,"NCT07623915","A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid in Patients With Hyperlipidemia Not Adequately Controlled by Statins","Inclusion Criteria:\n\n1\\. 18 years and older. 2. 18.5 kg\u002Fm2 ≤Body Mass Index (BMI) ≤35 kg\u002Fm2. 3. Diagnosis with ASCVD or have high-risk ASCVD, and\u002For diagnosis with HeFH.4.Be on stable lipid-modifying therapy for at least 4 weeks prior to screening, including moderate to high-dose statins with or without other lipid-modifying therapy (cholesterol absorption inhibitors\\[ezetimibe, Hyzetimibe\\]，fibrates \\[except gemfibrozil\\]）; 5.Fasting LDL-C must meet any one of the following\n\n1. For participants with high risk of ASCVD: LDL-C ≥ 2.6 mmol\u002FL (or 100 mg\u002FdL);\n2. For participants with extremely high risk of ASCVD: LDL-C≥ 1.8 mmol\u002FL (or 70 mg\u002FdL); 3) For participants with ultra-high risk of ASCVD: LDL-C≥ 1.4 mmol\u002FL (or 55 mg\u002FdL).\n\n6.Fully understand the purpose and requirements of the study, voluntarily participate in the clinical trial, and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Known allergy to any component of the investigational drug or its excipients or related preparations, or a history of allergic diseases (e.g., asthma, urticaria, eczema) or allergic constitution.\n2. Diagnosis with HoFH.\n3. History of tendon diseases or tendon ruptures before the screening.\n4. Severe, uncontrolled concomitant conditions that may affect drug absorption or have a significant impact on lipid level.\n5. Hyperthyroidism or uncontrolled hypothyroidism\n6. Uncontrolled hypertension\n7. Severe cardiovascular or cerebrovascular events in the past 3 months\n8. History of nephrotic syndrome or glomerulonephritis or severe renal dysfunction.\n9. Liver disease or dysfunction","ALL","18 Years",{"count":19,"type":20},222,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This trial is a multicenter randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of Bempedoic Acid Tablets in patients with hyperlipidemia not adequately controlled by Statins.",[26],"Primary Hyperlipidemia","NOT_YET_RECRUITING","2026-05-29",{"date":30,"type":31},"2026-06-03","ACTUAL",{"date":33,"type":20},"2026-06-12",{"date":35,"type":20},"2027-08-28",{"name":37,"class":38},"CSPC Ouyi Pharmaceutical Co., Ltd.","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100632855","phase-1-study-evaluating-the-safety-efficacy-and-pharmacokinetics-of-syh9089-injection-in-patients-undergoing-abdominal-surgery-100632855","NCT07519109","Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.","A Multicenter, Randomized, Double-Blind, Active Drug and Placebo Parallel-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety , Pharmacokinetics, and Efficacy of SYH9089 Injection in Patients Undergoing Abdominal Surgery","Inclusion Criteria:\n\n* 1\\. Fully understand the purpose and significance of this study, voluntarily participate in this study, voluntarily sign the informed consent, and voluntarily abide by the process of this study; 2. 18 years old ≤ age ≤75 years old, regardless of gender; 3. 19.0kg\u002Fm2≤BMI≤28.0kg\u002Fm2, ≥50.0kg for men and ≥45.0kg for women; 4. American Society of Anesthesiologists (ASA) grade I-II; 5. Elective abdominal surgery under general anesthesia, and the anticipated surgical incision is approximately 8-10 cm (inclusive), including at least one single incision of ≥ 5 cm in length; 6. Can understand the research process and the use of various scales involved in this study, and can effectively communicate with researchers.\n\nExclusion Criteria:\n\n* 1\\. Patients with a history of hypersensitivity to the investigational drug, comparator drug, surgical anesthetics, rescue analgesic drugs, or other drugs that may be used during the trial; 2. Patients with a history of drug abuse\u002Fsubstance use, or those with positive results on a drug abuse screening; 3. Patients with neurological\u002Fpsychiatric, respiratory, endocrine, hematologic, musculoskeletal, gastrointestinal, cardiovascular systems, or hepatic\u002Frenal diseases, judged by the investigator to be unsuitable for the trial; 4. Patients with a history of diabetes mellitus; 5. Patients with a history of myocardial infarction or unstable angina within 1 year prior to randomization; 6. Patients scheduled to undergo purely diagnostic exploratory surgery or palliative tumor resection, judged by the investigator to be unsuitable for the trial; 7. Patients with advanced malignant tumors with extensive metastasis during the screening period, judged by the investigator to be unsuitable for the trial; 8. Combined with other pain conditions that may confound the evaluation of postoperative pain according to the investigator; 9. Patients with a history of severe or refractory postoperative nausea or vomiting; 10. Use of the following drugs for less than 5 half-lives before randomization (based on the actual drug instructions; or within 7 days prior to randomization if the half-life is unclear) which, in the investigator's judgement, may affect the evaluation of analgesic efficacy. These include, but are not limited to: narcotics (opioids), local anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), sedative-hypnotics, non-benzodiazepines, sedative anesthetics, glucocorticoids (except for topical use), antiepileptics, anxiolytics, antidepressants, as well as Chinese herbal medicines or proprietary Chinese medicines with sedative or analgesic effects; 11. Use of strong CYP1A2 inhibitors for less than 5 half-lives before randomization (e.g., atazanavir, ciprofloxacin, enoxacin, fluvoxamine, ethinylestradiol) ； 12. Subjects with abnormal findings during the screening period (prior to admission) in vital signs, physical examination, 12-lead ECG, or laboratory tests, which in the investigator's judgement make the subject unsuitable for participation in this trial, including:\n\n  1. Patientss with poorly controlled blood pressure despite medication: systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg; or systolic blood pressure \\\u003C90 mmHg;\n  2. 12-lead ECG: QTcF ≥450 ms for males or ≥470 ms for females, or a history of severe arrhythmias such as second-degree type II or higher atrioventricular block, or a history of cardiac insufficiency;\n  3. Coagulation function: PT \\> ULN + 3 seconds and\u002For APTT \\> ULN + 10 seconds;\n  4. Liver function: ALT and\u002For AST ≥ 2 × ULN; TBIL ≥ 1.5 × ULN; ALB \\\u003C 30 g\u002FL;\n  5. Renal function: Cr ≥ 1.5 × ULN;\n  6. PLT \\\u003C 80 × 10\\^9\u002FL;\n  7. HGB \\\u003C 90 g\u002FL;\n  8. Random blood glucose \\> 11.1 mmol\u002FL. 13. Positive for HBsAg, HCV-Ab, HIV-Ab, or TP-Ab;; 14. Female subjects with a positive pregnancy test or who are breast feeding; fertile subjects who plan to become pregnant, are unwilling or unable to use effective contraception during the trial and within 3 months after administration, or who plan to donate sperm or ova; 15. Patients with a history of drug abuse, substance use, and\u002For alcoholism within 6 months prior to randomization, (alcoholism is defined as alcohol consumption exceeding 14 units per week:1 unit = 360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine); 16. Patients who underwent major surgery within 3 months prior to randomization, or surgery that may significantly affect the in vivo metabolism of the investigational product or the evaluation of safety; 17. Patients with blood loss or blood donation exceeding 400 mL, or who received blood transfusion or blood products within 3 months prior to randomization; 18. Patients who participated in any clinical trial of drugs or medical devices within 3 months prior to randomization; 19. Any other conditions judged by the investigator to be unsuitable for participation in this trial.","75 Years",{"count":48,"type":20},60,[50],"PHASE1","This is a randomized, double-blind, active drug- and placebo-controlled, dose-escalation clinical study conducted in patients scheduled to undergo abdominal surgery. It aims to evaluate the tolerability, safety, pharmacokinetics, and efficacy of SYH9089 Injection for postoperative analgesia in these patients.",[53],"Postoperative Pain","2026-04-02",{"date":56,"type":31},"2026-04-09",{"date":58,"type":20},"2026-03-31",{"date":60,"type":20},"2027-03-31",{"name":37,"class":38},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100559343","phase-2-study-to-evaluate-safety-and-efficacy-of-syhx1901-tablets-in-severe-alopecia-areata-patients-100559343","NCT06562894","Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients","A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata","Inclusion Criteria:\n\n1. Subjects fully understand and voluntarily participate in this study and sign informed consent;\n2. Subjects aged ≥18 to ≤ 65 years;\n3. Clinical diagnosis of alopecia areata,with at least 50% scalp hair loss，as defined by a SALT score ≥50 at screening and baseline visit;\n4. The current episode of hair loss was less than 10 years ago, and there was no evidence of spontaneous hair regrowth within 6 months before screening (the overall duration of alopecia areata more than 10 years could be included);\n5. Subjects must be volunteer and be able to understand informed consent Forms;\n6. Subjects and their partners should voluntarily take contraceptive measures considered effective by the investigator during the study period and for at least 28 days after the study;\n\nExclusion Criteria:\n\n1. Participants who have received hair implants;\n2. Alopecia caused by other reasons;\n3. Other active scalp or systemic diseases that may cause severe alopecia or affect the clinical evaluation of alopecia areata;\n4. Participants who have shaved their heads;\n5. Participants who have a clinically significant (as assessed by the investigator) abnormality in TSH or free T4 at screening and who were deemed by the investigator to be ineligible for the study;\n6. Participants who wore stick-on wigs and refused to stop wearing them during the study;\n7. Bacterial, fungal, or viral infection requiring hospitalization\u002Fintravenous treatment within 4 weeks before the first dose of study drug or requiring oral treatment within 2 weeks before the first dose of study drug;\n8. Have any chronic infection that requires systemic anti-infective therapy;\n9. Have received a live vaccine within 60 days before the first dose of the study drug or plan to receive a live vaccine between the middle of the study and 60 days after the end of the study;\n10. History of severe herpes zoster or sever herpes simplex infection;\n11. HBV-related tests are abnormal at screening;\n12. HCV antibody positive and HCV RNA positive at screening;\n13. Human immunodeficiency virus antibody positive or treponema pallidum antibody positive;\n14. Any known or suspected condition of congenital or acquired immunodeficiency;\n15. Previous or current active tuberculosis infection or latent tuberculosis infection (LTBI) deemed by the investigator\u002Fspecialist to require treatment;\n16. Major surgery within 8 weeks prior to first dose of the study drug or planned surgery during the study;\n17. Organ transplantation (except corneal transplantation more than 3 months before the initiation of the investigational drug);\n18. Symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with other chronic diseases that the investigator has determined are not suitable for participation in this clinical trial;\n19. History of malignancy or lymphoproliferative disease;\n20. Uncontrolled hypertension, systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg after systemic treatment;\n21. Having unstable cardiovascular disease defined as presence of a clinical cardiovascular event in the last 3 months or hospitalized for heart disease within the last 3 months; or NYHA≥grade 3, or abnormal ECG suggesting clinically significant and assessed by the investigator as carrying unforeseen risks;\n22. Patients with a history of arterial or venous thrombosis or high risk factors for thrombosis within 6 months before the first dose of study drug;\n23. Combined with active lipid-lowering drugs but poorly controlled hyperlipidemia: total cholesterol (TC)≥ 6.2mmol\u002FL or low-density lipoprotein cholesterol (LDL-C)≥3.4mmol\u002FL; or familial hypercholesterolemia (FH);","65 Years",{"count":71,"type":20},156,[73],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.",[76],"Severe Alopecia Areata",[78],"plaque psoriasis","2025-05-28",{"date":81,"type":31},"2025-06-03",{"date":83,"type":20},"2025-05-26",{"date":85,"type":20},"2027-11-17",{"name":37,"class":38},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100588634","phase-3-a-phase-iii-study-of-syhx1901-tablets-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-100588634","NCT06943950","A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis","A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\nSubjects fully understand and voluntarily participate in this study and sign informed consent; 2. Age ≥18 and ≤ 65 years old; 3. Subjects with a clinical diagnosis of stable moderate-to-severe plaque psoriasis with a history ≥6 months before randomization; Subjects with stable moderate-to-severe plaque psoriasis defined as meeting all four of the following criteria simultaneously:\n\n1. Subject must be diagnosed of chronic plaque psoriasis with no morphological changes or significant outbreaks of disease activity assessed by the investigator;\n2. Subject must be a candidate for systemic treatment or phototherapy assessed by the investigator;\n3. Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% at screening and baseline;\n4. PASI score of ≥10 and Static Physician's Global Assessment (sPGA) score ≥3 at screening and baseline; 4. Negative blood pregnancy results should be provided 7 days (inclusive) prior to randomization, and subjects and their partners should voluntarily take contraceptive measures considered effective by the investigator during the study period and for at least 28 days after the study; 5. Subjects must be volunteer and be able to complete study procedures and follow-up examinations.\n\nExclusion Criteria:\n\n1. Forms of psoriasis other than plaque psoriasis (Guttate psoriasis、erythrodermic psoriasis、Pustular psoriasis、Drug-induced psoriasis);\n2. Previous or current autoimmune disease that may affect the clinical evaluation of psoriasis;\n3. Other active skin conditions that may affect the clinical evaluation of psoriasis;\n4. Active bacterial, viral, fungal, or other infection that requires medical intervention;\n5. With progressive or uncontrolled systemic disease, or with chronic disease identified by the investigator as inappropriate for participation in the study;\n6. History of malignancy ;\n7. Any other medical and\u002For social reasons identified by the investigator as inappropriate for participation in the study;",{"count":95,"type":20},500,[23],"The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.",[99],"Moderate to Severe Plaque Psoriasis","2025-04-27",{"date":102,"type":31},"2025-04-30",{"date":104,"type":20},"2025-06-01",{"date":106,"type":20},"2027-06-30",{"name":37,"class":38},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100589767","phase-3-a-trial-of-dextromethorphan-and-bupropion-sustained-release-tablets-in-patients-with-major-depressive-disorder-100589767","NCT06958692","A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Adult Patients With Major Depressive Disorder","Inclusion Criteria:\n\n1. Male or female, Age 18 - 65, inclusive\n2. Currently meets DSM-5 diagnosis of MDD without psychotic features, Current major depressive episode of at least 4 weeks in duration at screening\n3. Identified as MDD by Mini-international Neuropsychiatric interview (M.I.N.I.)\n4. MADRS score ≥25 and CGI-S ≥4 at screening and baseline\n5. The results of physical examination and laboratory tests during the screening period meet the test requirements\n6. Body Mass Index between 18 and 40 kg\u002Fm2, inclusive\n7. For male subjects, use of an adequate method of birth control by the subject and by female sexual partners\n\nExclusion Criteria:\n\n* 1\\. The researchers determined that it was refractory depression \\[defined as in a current depressive episode or a previous depressive episode, After 2 or more antidepressants, a sufficient amount (in the maximum recommendation of the manual), a course of foot therapy (at least even Continued medication for 4-6 weeks) ineffective after treatment\\] 2. The MADRS score improved by ≥ 25% at baseline compared with the screening period.\n\n  3\\. Hospitalization in a psychiatric hospital during a current depressive episode 4. There is a clinically significant risk of suicide or self-harm and harm to others 5. Screening patients tested positive for substance abuse 6. In the investigator's judgment, there are any clinically significant oncology, hematology, or internal diseases that are not suitable for entry into the study Secretory\u002Fmetabolic, cardiovascular, respiratory, kidney, liver, gastrointestinal, infectious or nervous system fever Or suffer from an unstable or progressive chronic disease 7. hypertension 8. Hypothyroidism or hyperthyroidism, except for the following cases: receiving stable medication with no change in dose for at least 1 month before screening (serum TSH must be \\> 0.75×LLN（ Lower Limit of Normal ） and \\\u003C 1.25×ULN（Upper Limit of Normal ）) 9 Bupropion, dextromethorphan, opioids (such as codeine), or any of the study drugs Allergic to other ingredients 10. Presence of a history of intolerance to bupropion or dextromethorphan 11. People living with HIV, or testing positive for HIV during screening 12. Screening period hepatitis virology test positive 13. Liver enzyme test results during the screening period (total bilirubin, aspartate aminotransferase and\u002For alanine aminotransferase) \\> 2.0 × ULN 14. According to the investigator's judgment, other conditions are not suitable for participating in this clinical study",{"count":116,"type":20},388,[23],"A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive disorder.",[120],"Major Depressive Disorder (MDD)","RECRUITING",{"date":123,"type":31},"2025-05-06",{"date":125,"type":31},"2025-04-11",{"date":127,"type":20},"2026-12-30",{"name":37,"class":38},1,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100560001","phase-3-liposomal-irinotecan-in-combination-with-oxaliplatin-and-s-1-versus-gemcitabine-combined-with-capecitabine-as-postoperative-adjuvant-therapy-for-pancreatic-cancer-100560001","NCT06571461","Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","A Randomized, Open-label, Multi-center Phase III Clinical Study of Liposomal Irinotecan Combined With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine for Postoperative Adjuvant Treatment of Pancreatic Cancer","Inclusion Criteria:\n\n1. Patients able and willing to provide a written informed consent aged 18-75 years.\n2. Histologically confirmed resected ductal pancreatic adenocarcinoma (including adenosquamous carcinoma).\n3. Undergone radical resection and confirmed macroscopic complete resection (R0 and R1).\n4. Full recovery after surgery; able to start adjuvant treatment within 12 weeks after surgery.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n6. The main organs function well.\n\nExclusion Criteria:\n\n1. Patients with other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, pancreatoblastoma, and solid-pseudopapillary tumor.\n2. Macroscopic incomplete tumor removal (R2 resection).\n3. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma.\n4. Presence or history of metastatic or locally recurrent pancreatic adenocarcinoma.\n5. CA 19-9\\> 180 U \u002F ml within 21 days before randomization.\n6. The toxicity of previous therapy has not recovered to Grade 1 or below.\n7. Known peripheral neuropathy (CTCAE ≥ Grade 2).\n8. Known deficiency of dihydropyrimidine dehydrogenase (DPD)\n9. Subjects with a confirmed diagnosis of Gilbert's syndrome",{"count":138,"type":20},408,[23],"This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.",[142],"Pancreatic Cancer","2024-08-25",{"date":145,"type":31},"2024-08-27",{"date":147,"type":20},"2024-09",{"date":149,"type":20},"2029-03",{"name":37,"class":38},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":129},"100555411","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-syhx1901-tablet-in-non-segmental-vitiligo-patients-100555411","NCT06511739","A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients","A Phase 2 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients","Inclusion Criteria:\n\n1. Willing to sign an ICF, able to comprehend and comply with the study procedures.\n2. Male or female subjects aged 18 to 65，inclusive.\n3. Subjects with a clinical diagnosis of non-segmental vitiligo.\n4. Agree to stop all other treatments for vitiligo during the study period.\n5. Women of child-bearing potential must have a negative serum pregnancy test within 3 days prior to the first study agent administration.\n\nExclusion Criteria:\n\n1. Diagnosed as other active depigmentation disease.\n2. At screening or baseline visits, subject exhibits active inflammatory dermatologic disease or symptoms that in the opinion of investigators would interfere of vitiligo evaluation or response to treatment.\n3. Uncontrolled thyroid function at screening as determined by the investigator.\n4. Use of permanent depigmentation treatment or skin grafts.\n5. Use of phototherapy, topical or systemic treatments within certain time frame prior to Day1.\n6. Have active bacterial\u002Fvirus\u002Fother pathogens infection or infestation that require medical intervention.\n7. Have progressive or uncontrolled systemic disease, or other concomitant chronic disease that the investigators believe unsuitable to participate the study.\n8. History of alcohol and drug abuse within one year prior to screening; History of neurological or mental disorders with diagnosis records, such as severe depression, suicidal tendencies, epilepsy, dementia, etc.\n9. Have any other reasons determined by the investigator that the subject is not eligible for the study.",{"count":159,"type":20},144,[73],"A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.",[163],"Non-segmental Vitiligo","2024-07-15",{"date":166,"type":31},"2024-07-22",{"date":168,"type":31},"2024-05-27",{"date":170,"type":20},"2025-10-01",{"name":37,"class":38},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":129},"100543303","phase-2-a-study-to-evaluate-the-efficacy-and-safety-in-subjects-with-advanced-breast-cancer-treated-with-syhx2011-100543303","NCT06354114","A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011","A Single-arm Open-label Phase II Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011","Inclusion Criteria:\n\n* 1.Voluntarily sign the written informed consent and willing to cooperate with the research according to the requirements of the plan.\n* 2.Breast cancer confirmed by histology or cytology and meeting the following conditions:\n\n  1. According to the breast cancer diagnosis and treatment guidelines (2022) of the Chinese Society of Clinical Oncology (CSCO), the breast cancer patients who are suitable for anti-tumor treatment with paclitaxel for injection (albumin-bound) alone judged by the investigators.\n  2. According to RECIST 1.1 standard, there is at least one measurable lesion. For the lesions that have been treated with radiotherapy in the past, only if the disease progression is clear after radiotherapy, then the lesions can be included as the measurable lesions.\n* 3\\. Age ≥ 18 years.\n* 4\\. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 7 days before the first administration.\n* 5\\. Expected survival time ≥3 months.\n* 6\\. Normal function of main organs within 7 days before the first administration \\[no blood transfusion, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF) or other medical support treatment within 14 days before the first administration\\], meeting the following criteria:\n\n  1. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL; Platelet count (PLT)≥ 100 × 10\\^9\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL.\n  2. AST \\& ALT ≤ 10 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Serum creatinine ≤ 1.5 × ULN and Creatinine clearance ≥ 30 mL\u002Fmin.\n  3. Activated partial thrombin time (APTT) \u002FProthrombin time (PT)\u002FInternational standardized ratio (INR)≤1.5 × ULN.\n* 7\\. The patients with fertility agreed to use reliable contraceptive measures (such as intrauterine device \\[IUD\\], contraceptives or condoms) during the study period and within 6 months after the end of the study; The serum pregnancy test of women of childbearing age is negative within 7 days before the study enrollment.\n\nExclusion Criteria:\n\n* 1\\. History of severe allergy or major hypersensitivity to paclitaxel or human serum albumin (NCI-CTCAE Version 5.0, ≥ Level 3).\n* 2\\. The toxicity of previous anti-tumor treatment has not recovered (NCI-CTC AE 5.0, \\>Level 1); Skin reaction or other hypersensitivity caused by any reason does not return to normal.\n* 3\\. Patients with symptomatic brain metastasis or meningeal metastasis, or there is any evidence that shows uncontrolled brain metastasis or meningeal metastasis.\n* 4\\. History of malignant tumors other than breast cancer within 5 years before the first administration, except for tumors that have recovered after treatment, such as carcinoma in situ, basal cell carcinoma, etc.\n* 5\\. There are any of the following concomitant diseases:\n\n  1. Serious or uncontrolled cardiovascular diseases: such as chronic congestive heart failure of grade Ⅱ or above (NYHA standard), uncontrolled hypertension (systolic blood pressure\\>150 mmHg and\u002For diastolic blood pressure\\>90 mmHg after regular treatment), etc.\n  2. There are clearly identified neurological diseases (such as epilepsy, dementia, etc.) and ≥ grade 3 peripheral neuropathy.\n  3. Serious respiratory diseases, such as asthma requiring glucocorticoid drugs, chronic obstructive pulmonary disease (acute exacerbation), etc.\n  4. Uncontrolled diabetes (fasting blood glucose ≥ 10 mmol\u002FL after regular treatment).\n  5. Serious chronic or active infection requiring systemic antibacterial, antifungal, or antiviral treatment (such as anti-infective drugs have been used for more than one week before the first administration and will continue to be used), including tuberculosis infection, etc.\n  6. Active HBV (HBsAg positive patients need to be tested for HBV DNA, which will be excluded if the HBV DNA is greater than the upper limit of the normal value) or HCV infection (patients with polymerase chain reaction (PCR) HCV RNA within the normal value range can participate in this study) or syphilis antibody positive (and confirmed) or HIV positive.\n  7. Rash on any part of the body and any disease that may cause skin reactions, such as cholestasis, systemic lupus erythematosus, eczema, allergic dermatitis, atopic dermatitis, herpes zoster, psoriasis, etc.\n* 6\\. Have the following previous medical history:\n\n  1. Major surgical operations (such as abdominal and thoracic major operations; excluding minor operations such as diagnostic puncture or infusion device implantation) have been performed within 28 days before the first administration of the study treatment, or major surgical treatment is expected to be required during the study period.\n  2. Serious cardio-cerebrovascular diseases occurred within 6 months before the first administration, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident (lacunar cerebral infarction without clinical significance can be included), etc.\n* 7\\. The following previous\u002Fconcomitant drugs or therapies exist:\n\n  1. Those who use glucocorticoids or antihistamines or other drugs with therapeutic or preventive effects on rash within 2 weeks or 5 half-lives (whichever is longer) before the first administration.\n  2. Use of chemical small molecule antitumor drugs (including endocrine therapy) within 2 weeks or use of biological macromolecule anti-tumor, biological therapy, radiotherapy within 4 weeks before the first administration. Those who need to be treated with other anti-tumor drugs during the study.\n  3. Vaccinated within 4 weeks before the first administration or expected to be vaccinated during the observation period of study administration.\n  4. Those who are expected to undergo radiotherapy or hemodialysis within 2 months after the first administration.\n* 8\\. Patients who are pregnant, nursing or planning to become pregnant during the study.\n* 9\\. Other situations in which the investigator judged that the patient was not suitable for the study.",{"count":180,"type":20},80,[73],"The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011",[184],"Advanced Breast Cancer","2024-04-03",{"date":187,"type":31},"2024-04-09",{"date":189,"type":20},"2024-04",{"date":191,"type":20},"2026-12",{"name":37,"class":38},""]